

# BIMZELX<sup>®</sup> 101

**Bimzelx<sup>®</sup>**  
(bimekizumab-bkzx)

An overview of need-to-knows about BIMZELX for you and your patients

**USE:**  
BIMZELX is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy.

## MECHANISM OF ACTION

BIMZELX (bimekizumab-bkzx) is the first and only approved biologic to selectively target the overly expressed IL-17A and IL-17F cytokines in plaque psoriasis

## DOSING WITH BIMZELX

**6 doses for the first year once initial dosing is complete.\***

\*Following 5 initial doses during the first 16 weeks of treatment. Some patients weighing 264 lbs (120 kg) or more may be prescribed maintenance doses every 4 weeks after week 16.

- Your patients will start with a series of 5 doses, each taken 4 weeks apart
  - Following that, your patients will need only 1 dose every 8 weeks
- All doses are 320 mg, given as 2 separate injections under the skin of 160 mg each.

**START WITH 1 DOSE**



**EVERY 4 WEEKS FOR 5 DOSES**

● Every 4 weeks

**CONTINUE WITH 1 DOSE**



**EVERY 8 WEEKS**

● Every 8 weeks

## ADMINISTERING BIMZELX

**Getting your patients comfortable with self-injection.**

BIMZELX is administered under the skin (subcutaneously) by an autoinjector or a prefilled syringe. After training, your patient or their caregiver will administer BIMZELX at home using one of these two devices.

**AUTOINJECTOR**



**PREFILLED SYRINGE**



Your patients can become more familiar with the process of administering BIMZELX by visiting [BIMZELX.com](https://www.bimzelx.com) to watch step-by-step demonstration videos of the proper procedure for injection. This link will also provide other helpful tips and resources for your patients.

## IMPORTANT SAFETY INFORMATION

### Suicidal Ideation and Behavior

BIMZELX® (bimekizumab-bkzx) may increase the risk of suicidal ideation and behavior (SI/B). A causal association between treatment with BIMZELX and increased risk of SI/B has not been established. Prescribers should weigh the potential risks and benefits before using BIMZELX in patients with a history of severe depression or SI/B. Advise monitoring for the emergence or worsening of depression, suicidal ideation, or other mood changes. If such changes occur, advise to promptly seek medical attention, refer to a mental health professional as appropriate, and re-evaluate the risks and benefits of continuing treatment.

### Infections

BIMZELX may increase the risk of infections. Do not initiate treatment with BIMZELX in patients with any clinically important active infection until the infection resolves or is adequately treated. In patients with a chronic infection or a history of recurrent infection, consider the risks and benefits prior to prescribing BIMZELX. Instruct patients to seek medical advice if signs or symptoms suggestive of clinically important infection occur. If a patient develops such an infection or is not responding to standard therapy, monitor the patient closely and do not administer BIMZELX until the infection resolves.

### Tuberculosis

Evaluate patients for tuberculosis (TB) infection prior to initiating treatment with BIMZELX. Avoid the use of BIMZELX in patients with active TB infection. Initiate treatment of latent TB prior to administering BIMZELX. Consider anti-TB therapy prior to initiation of BIMZELX in patients with a past history of latent or active TB in whom an adequate course of treatment cannot be confirmed. Closely monitor patients for signs and symptoms of active TB during and after treatment.

### Liver Biochemical Abnormalities

Elevated serum transaminases were reported in clinical trials with BIMZELX. Test liver enzymes, alkaline phosphatase and bilirubin at baseline, periodically during treatment with BIMZELX and according to routine patient management. If treatment-related increases in liver enzymes occur and drug-induced liver injury is suspected, interrupt BIMZELX until a diagnosis of liver injury is excluded. Permanently discontinue use of BIMZELX in patients with causally associated combined elevations of transaminases and bilirubin. Avoid use of BIMZELX in patients with acute liver disease or cirrhosis.

### Inflammatory Bowel Disease

Cases of inflammatory bowel disease (IBD) have been reported in patients treated with IL-17 inhibitors, including BIMZELX. Avoid use of BIMZELX in patients with active IBD. During BIMZELX treatment, monitor patients for signs and symptoms of IBD and discontinue treatment if new onset or worsening of signs and symptoms occurs.

### Immunizations

Prior to initiating therapy with BIMZELX, complete all age-appropriate vaccinations according to current immunization guidelines. Avoid the use of live vaccines in patients treated with BIMZELX.

## MOST COMMON ADVERSE REACTIONS

Most common adverse reactions ( $\geq 1\%$ ) are upper respiratory infections, oral candidiasis, headache, injection site reactions, tinea infections, gastroenteritis, Herpes Simplex Infections, acne, folliculitis, other Candida infections, and fatigue.



Inspired by patients.  
Driven by science.

BIMZELX® is a registered trademark of the UCB Group of Companies.  
All other trademarks and registered trademarks are the property of their respective holders.

©2023 UCB, Inc., Smyrna, GA 30080.  
All rights reserved. Printed in the USA.  
US-P-BK-PSO-2200170